



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 


PRODUCT INFORMATION



IQA

Item No. 35223

CAS Registry No.: 391670-48-7
Formal Name: 5,6-dihydro-5-oxo-indolo[1,2-a]quinazoline-7-acetic acid
Synonym: CGP 029482
MF: C₁₇H₁₂N₂O₃
FW: 292.3
Purity: ≥90%
UV/Vis.: λ_{max}: 226, 259, 298 nm
Supplied as: A solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

IQA is supplied as a solid. A stock solution may be made by dissolving the IQA in the solvent of choice, which should be purged with an inert gas. IQA is soluble in the organic solvent DMSO at a concentration of approximately 10 mg/ml.

Description

IQA is a casein kinase 2 (CK2) inhibitor (IC₅₀ = 0.39 μM).¹ IQA is selective for CK2 over protein kinase A (PKA), glycogen synthase kinase 3β (GSK3β), lymphocyte cell-specific protein tyrosine kinase (LCK), dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A), and PI3Kγ (IC₅₀s = 16, 14, 11, 8, and >200 μM, respectively). IQA decreases the viability of Jurkat leukemia cells in a concentration-dependent manner.²

References

1. Sarno, S., De Moliner, E., Ruzzene, M., *et al.* Biochemical and three-dimensional-structural study of the specific inhibition of protein kinase CK2 by [5-oxo-5,6-dihydroindolo-(1,2-a)quinazolin-7-yl]acetic acid (IQA). *Biochem. J.* **374**, 639-646 (2003).
2. Sarno, S., Ruzzene, M., Frascella, P., *et al.* Development and exploitation of CK2 inhibitors. *Mol. Cell. Biochem.* **274**(1-2), 69-76 (2005).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 09/29/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM